Literature DB >> 27888878

The Spectrum of Double Hit Lymphomas.

Jeremy S Abramson1.   

Abstract

Double-hit lymphomas (DHLs) characterize a unique subset of B-cell non-Hodgkin lymphomas. DHL typically presents in older adults with high-risk clinical features. This entity carries a significantly inferior prognosis compared with typical cases of diffuse large B-cell lymphoma; however, emerging literature can identify discrete clinical features within DHL that are associated with a favorable prognosis. Emerging literature is also demonstrating that intensive upfront treatment strategies may improve outcome. Diagnosis, prognostication, and management of DHL are reviewed, as well as potential future directions incorporating novel biologically targeted therapies. Finally, double-expressing lymphomas (DELs) will be discussed and contrasted with DHL. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCL2; Double-expressing lymphomas; Double-hit lymphomas; High grade B-cell lymphoma; MYC

Mesh:

Year:  2016        PMID: 27888878     DOI: 10.1016/j.hoc.2016.07.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

1.  Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.

Authors:  George Daniel Grass; Matthew N Mills; Kamran A Ahmed; Casey L Liveringhouse; Michael E Montejo; Timothy J Robinson; Julio C Chavez; Louis B Harrison; Sungjune Kim
Journal:  Leuk Lymphoma       Date:  2018-11-20

2.  BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma.

Authors:  Anna Esteve-Arenys; Gael Roue
Journal:  Oncoscience       Date:  2018-04-29

3.  High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma.

Authors:  Alison M Moore; Olga Moshkin; Gordon J Swain; Susan Crocker; David P LeBrun
Journal:  Diagn Pathol       Date:  2018-05-24       Impact factor: 2.644

Review 4.  Germinal center-derived lymphomas: The darkest side of humoral immunity.

Authors:  Coraline Mlynarczyk; Lorena Fontán; Ari Melnick
Journal:  Immunol Rev       Date:  2019-03       Impact factor: 12.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.